Prevention of etomidate induced myoclonus by use of pregabalin

The efficacy of pregabalin for prevention of etomidate-induced myoclonus: a prospective, randomized, placebo-controlled, double-blind study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/03/007978

Enrollment

Registered

2017-03-01

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- ASA grade I or II patient, Non diabetic, Non hypertensive

Interventions

Intervention1: Pregabalin: Patients will be received Pregabalin 150 mg orally 1 hour before the induction of anesthesia with sips of water Control Intervention1: Similar looking vitamin B complex caps

Eligibility

Inclusion criteria

Inclusion criteria: 1.ASA grade I and II, 2.non hypertensive and non diabetic 3.scheduled for surgery under general anesthesia

Exclusion criteria

Exclusion criteria: 1.patients with known sensitivity to pregabalin, 2.seizure disorders, who were taking pregabalin or gabapentin, 3.history of drug or alcohol abuse, 4.history of chronic pain or daily intake of analgesics, 5.pregnant or breast-feeding females, 6.uncontrolled medical disease (diabetes mellitus and hypertension) 7.impaired kidney or liver functions and 8.psychiatric patients

Design outcomes

Primary

Measure	Time frame
Incidence and severity of myoclonusTimepoint: Myoclonus within ninety seconds after etomidate injection	—

Secondary

Measure	Time frame
Postoperative sedation scoreTimepoint: Postoperative period within 1 hr	—

Countries

India

Contacts

Public ContactDr Vinit Kumar Srivastava

Apollo Hospitals Bilaspur

drvinit75@gmail.com9755557539

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026